Company intelligence / Profile preview

Hale Therapeutics

Philadelphia, Pennsylvania, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hale Therapeutics has developed and launched a connected medical vaporizer and mobile app designed to help users quit smoking by gradually reducing nicotine intake. There are no published clinical trial results, but the product is positioned as an alternative or improvement over traditional nicotine replacement therapies.

Therapeutic areas: Psychiatry
Modalities: DeviceDigital therapy
Industry: Therapeutic Medical Devices

Partnerships

AlphaLab Health AcceleratorBen Franklin Technology Partners of Southeastern PABackstage AcceleratorMonozukuri Ventures

Beyond the preview

Go deeper on Hale Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hale Therapeutics.

Explore the full profile